Discovery of an Unexpected Similarity in Ligand Binding between BRD4 and PPARγ

被引:2
作者
Humbeck, Lina [1 ,2 ]
Pretzel, Jette [1 ]
Spitzer, Saskia [1 ]
Koch, Oliver [1 ,3 ]
机构
[1] TU Dortmund Univ, Fac Chem & Chem Biol, D-44227 Dortmund, Germany
[2] Boehringer Ingelheim Pharma GmbH & Co KG, Computat Chem, Med Chem, Birkendorferstr 65, D-88397 Biberach, Germany
[3] Westfalische Wilhelms Univ Munster, Inst Pharmaceut & Med Chem, D-48149 Munster, Germany
关键词
DRUG DISCOVERY; PROTEIN; INHIBITORS; DESIGN; POTENT; VISUALIZATION; PHARMACOLOGY; EXPLORATION; UNIVERSE; TARGET;
D O I
10.1021/acschembio.1c00323
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Knowledge about interrelationships between different proteins is crucial in fundamental research for the elucidation of protein networks and pathways. Furthermore, it is especially critical in chemical biology to identify further key regulators of a disease and to take advantage of polypharmacology effects. Here, we present a new concept that combines a scaffold-based analysis of bioactivity data with a subsequent screening to identify novel inhibitors for a protein target of interest. The initial scaffold-based analysis revealed a flavone-like scaffold that can be found in ligands of different unrelated proteins indicating a similarity in ligand binding. This similarity was further investigated by testing compounds on bromodomain-containing protein 4 (BRD4) that were similar to known ligands of the other identified protein targets. Several new BRD4 inhibitors were identified and proven to be validated hits based on orthogonal assays and X-ray crystallography. The most important discovery was an unexpected relationship between BRD4 and peroxisome-proliferator activated receptor gamma (PPAR gamma). Both proteins share binding site similarities near a common hydrophobic subpocket which should allow the design of a polypharmacology-based ligand targeting both proteins. Such dual-BRD4-PPAR gamma modulators open up new therapeutic opportunities, because both are important drug targets for cancer therapy and many more important diseases. Thereon, a complex structure of sulfasalazine was obtained that involves two bromodomains and could be a potential starting point for the design of a bivalent BRD4 inhibitor.
引用
收藏
页码:1255 / 1265
页数:11
相关论文
共 50 条
  • [31] Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA
    Zou, Z.
    Huang, B.
    Wu, X.
    Zhang, H.
    Qi, J.
    Bradner, J.
    Nair, S.
    Chen, L-F
    ONCOGENE, 2014, 33 (18) : 2395 - 2404
  • [32] Diving into the Water: Inducible Binding Conformations for BRD4, TAF1(2), BRD9, and CECR2 Bromodomains
    Crawford, Terry D.
    Tsui, Vickie
    Flynn, E. Megan
    Wang, Shumei
    Taylor, Alexander M.
    Cote, Alexandre
    Audia, James E.
    Beresini, Maureen H.
    Burdick, Daniel J.
    Cummings, Richard
    Dakin, Les A.
    Duplessis, Martin
    Good, Andrew C.
    Hewitt, Michael C.
    Huang, Hon-Ren
    Jayaram, Hariharan
    Kiefer, James R.
    Jiang, Ying
    Murray, Jeremy
    Nasveschuk, Christopher G.
    Pardo, Eneida
    Poy, Florence
    Romero, F. Anthony
    Tang, Yong
    Wang, Jian
    Xu, Zhaowu
    Zawadzke, Laura E.
    Zhu, Xiaoyu
    Albrecht, Brian K.
    Magnuson, Steven R.
    Bellon, Steve
    Cochran, Andrea G.
    JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (11) : 5391 - 5402
  • [33] Discovery and structure-activity relationship studies of N6-benzoyladenine derivatives as novel BRD4 inhibitors
    Noguchi-Yachide, Tomomi
    Sakai, Taki
    Hashimoto, Yuichi
    Yamaguchi, Takao
    BIOORGANIC & MEDICINAL CHEMISTRY, 2015, 23 (05) : 953 - 959
  • [34] Identification of a novel ligand for the ATAD2 bromodomain with selectivity over BRD4 through a fragment growing approach
    Miller, Duncan C.
    Martin, Mathew P.
    Adhikari, Santosh
    Brennan, Alfie
    Endicott, Jane A.
    Golding, Bernard T.
    Hardcastle, Ian R.
    Heptinstall, Amy
    Hobson, Stephen
    Jennings, Claire
    Molyneux, Lauren
    Ng, Yvonne
    Wedge, Stephen R.
    Noble, Martin E. M.
    Cano, Celine
    ORGANIC & BIOMOLECULAR CHEMISTRY, 2018, 16 (11) : 1843 - 1850
  • [35] Interplay between interferon regulatory factor 1 and BRD4 in the regulation of PD-L1 in pancreatic stellate cells
    Ebine, Kazumi
    Kumar, Krishan
    Pham, Thao N.
    Shields, Mario A.
    Collier, Katharine A.
    Shang, Meng
    DeCant, Brian T.
    Urrutia, Raul
    Hwang, Rosa F.
    Grimaldo, Sam
    Principe, Daniel R.
    Grippo, Paul J.
    Bentrem, David J.
    Munshi, Hidayatullah G.
    SCIENTIFIC REPORTS, 2018, 8
  • [36] Discovery of potent and selective BRD4 inhibitors capable of blocking TLR3-induced acute airway inflammation
    Liu, Zhiqing
    Tian, Bing
    Chen, Haiying
    Wang, Pingyuan
    Brasier, Allan R.
    Zhou, Jia
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 151 : 450 - 461
  • [37] Acetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors
    Ember, Stuart W. J.
    Zhu, Jin-Yi
    Olesen, Sanne H.
    Martin, Mathew P.
    Becker, Andreas
    Berndt, Norbert
    Georg, Gunda I.
    Schoenbrunn, Ernst
    ACS CHEMICAL BIOLOGY, 2014, 9 (05) : 1160 - 1171
  • [38] NMR Molecular Replacement Provides New Insights into Binding Modes to Bromodomains of BRD4 and TRIM24
    Torres, Felix
    Walser, Reto
    Kaderli, Janina
    Rossi, Emanuele
    Bobby, Romel
    Packer, Martin J.
    Sarda, Sunil
    Walker, Graeme
    Hitchin, James R.
    Milbradt, Alexander G.
    Orts, Julien
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (07) : 5565 - 5574
  • [39] Molecular design of Stat3-derived peptide selectivity between BET proteins Brd2 and Brd4 in ovarian cancer
    Zhu, Lixia
    Ding, Xi
    JOURNAL OF MOLECULAR RECOGNITION, 2018, 31 (02)
  • [40] S100A4 participates in sepsis-induced endothelial cell inflammatory response and barrier damage by binding to BRD4
    Chen, Xiujing
    Yang, Ping
    CLINICAL HEMORHEOLOGY AND MICROCIRCULATION, 2025,